河北医科大学学报

• 论著 • 上一篇    下一篇

乌司他丁联用生长抑素治疗新生儿消化道畸形术后消化道出血的有效性与安全性评价

  

  1. 河北省唐山市妇幼保健院小儿外科,河北 唐山 063000
  • 出版日期:2017-11-25 发布日期:2017-11-16
  • 作者简介:陈永满(1978-),女,河北唐山人,河北省唐山市妇幼保健院主治医师,医学学士,从事小儿外科疾病诊治研究。
  • 基金资助:
    河北省医学科学研究重点课题(20171338)

Evaluation of efficacy and safety of ulinastatin combined with somatostatin in the treatment of postoperative gastrointestinal hemorrhage in neonates with gastrointestinal malformation

  1. Department of Pediatric Surgery; Maternal and Child Health Hospital of Tangshan, Hebei Province, Tangshan 063000, China
  • Online:2017-11-25 Published:2017-11-16

摘要: 摘要]〓
〖HTH〗目的〖HTSS〗〖KG*2〗评价乌司他丁联用生长抑素治疗新生儿消化道畸形术后消化道出血的有效性与安全性。
〖HTH〗方法〖HTSS〗〖KG*2〗选择消化道畸形术后并发消化道出血的新生儿42例,按照随机数字表法分为对照组和观察组各21例。对照组在常规止血治疗基础上加用生长抑素治疗,观察组常规止血+生长抑素+乌司他丁治疗。对比2组临床疗效及不良反应发生情况。
〖HTH〗结果〖HTSS〗〖KG*2〗观察组临床疗效优于对照组,治疗总有效率高于对照组(P<005);观察组胃肠减压引流液隐血试验转阴时间明显短于对照组(P<005),24 h血红蛋白下降值明显低于对照组(P<005);2组总体不良反应发生率差异无统计学意义(P>005)。
〖HTH〗结论〖HTSS〗〖KG*2〗乌司他丁联用生长抑素治疗新生儿消化道畸形术后消化道出血疗效显著,且未明显增加药物不良反应,安全性较高,值得临床推广应用。

关键词: 胃肠出血, 乌司他丁, 生长抑素, 婴儿, 新生

Abstract: [Abstract]  Objective〖HTSS〗〓To evaluate the efficacy and safety of ulinastatin combined with somatostatin in the treatment of digestive tract hemorrhage in neonates with digestive tract malformation.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓Fortytwo neonates with digestive tract hemorrhage after digestive tract malformation were selected. They were divided into control group and observation group according to the random number table, each with 21 cases. The control group was treated with somatostatin on the basis of routine hemostasis, and the observation group was treated with routine hemostasis+somatostatin+ulinastatin. The clinical efficacy and adverse reactions of the 2 groups were compared and analyzed.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓the clinical curative effect of observation group than the control group, the total efficiency of treatment was higher than the control group(P<0.05). Observation group of gastrointestinal decompression drainage test of occult blood clearance time was significantly shorter than the control group(P<0.05), 24 h decrease in hemoglobin was significantly lower than the control group(P<0.05). Adverse reactions of the 2 groups had no significant difference in the rate of total body the difference(P>0.05).
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓 Ulinastatin combined with somatostatin in the treatment of digestive tract hemorrhage in neonates with digestive tract hemorrhage has significant curative effect, and has no obvious adverse drug reactions. It is safe and worthy of clinical application 

Key words: gastrointestinal hemorrhage; ulinastatin, somatostatin, infant, newborn